The Relapse-to-Therapy Interval in Relapsed or Refractory Diffuse Large B Cell Lymphoma Is Associated with Clinical OutcomesPaolo F. Caimi, Christine Auberle,Krishna Goparaju,Molly Megan Gallogly,Firas Baidoun,Amanda F Cashen,Brian T. HillBlood(2023)引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要